ArticleFrontiers in oncology2025
Development and validation of a prognostic nomogram for unresectable pancreatic ductal adenocarcinoma with synchronous liver metastases: a study based on the SEER database and an external cohort.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pancreatic ductal adenocarcinoma with synchronous liver metastases (PDACLM) represents a highly aggressive malignancy with limited treatment options and poor prognosis. While conversion therapy may enable curative surgery in a small subset of patients, the majority ultimately remain ineligible for resection. Prognostic tools tailored to this unresected population are lacking but urgently needed for guiding clinical decisions. Methods: We conducted a retrospective cohort study using 9,469 patients with histologically confirmed PDACLM from the SEER database (2010-2015), supplemented by an external validation cohort of 94 patients treated at the Second Affiliated Hospital of Chongqing Medical University (2020-2023). Multivariate Cox regression analysis was used to identify independent prognostic factors. A nomogram was constructed and validated internally and externally to predict individualized overall survival (OS) at 12, 18, and 24 months. Results: Age ≥65 years, higher tumor grade, and undetermined nodal status were independently associated with reduced OS, while chemotherapy, radiotherapy, and metastasis-directed surgery significantly improved survival outcomes (all P<0.05). The nomogram demonstrated good discriminative performance with a C-index of 0.73 in the training cohort and 0.72 in internal validation. External validation showed consistent predictive accuracy (C-index: 0.715). Calibration plots and decision curve analyses supported the model's reliability and clinical utility. Conclusion: We developed and externally validated a clinically accessible nomogram for survival prediction in unresected PDACLM patients. This tool may assist clinicians in risk stratification and treatment planning for a frequently overlooked patient subgroup. Further prospective validation is warranted to confirm its applicability in broader clinical settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.